Cancer and Metastasis Reviews最新文献_第4页

Mechanical deformation and death of circulating tumor cells in the bloodstream. 血液中循环肿瘤细胞的机械变形和死亡。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1007/s10555-024-10198-3

Yunxiu Qiu, Tong Gao, Bryan Ronain Smith

{"title":"Mechanical deformation and death of circulating tumor cells in the bloodstream.","authors":"Yunxiu Qiu, Tong Gao, Bryan Ronain Smith","doi":"10.1007/s10555-024-10198-3","DOIUrl":"10.1007/s10555-024-10198-3","url":null,"abstract":"The circulation of tumor cells through the bloodstream is a significant step in tumor metastasis. To better understand the metastatic process, circulating tumor cell (CTC) survival in the circulation must be explored. While immune interactions with CTCs in recent decades have been examined, research has yet to sufficiently explain some CTC behaviors in blood flow. Studies related to CTC mechanical responses in the bloodstream have recently been conducted to further study conditions under which CTCs might die. While experimental methods can assess the mechanical properties and death of CTCs, increasingly sophisticated computational models are being built to simulate the blood flow and CTC mechanical deformation under fluid shear stresses (FSS) in the bloodstream.Several factors contribute to the mechanical deformation and death of CTCs as they circulate. While FSS can damage CTC structure, diverse interactions between CTCs and blood components may either promote or hinder the next metastatic step-extravasation at a remote site. Overall understanding of how these factors influence the deformation and death of CTCs could serve as a basis for future experiments and simulations, enabling researchers to predict CTC death more accurately. Ultimately, these efforts can lead to improved metastasis-specific therapeutics and diagnostics specific in the future.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1489-1510"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial disparity in prostate cancer: an outlook in genetic and molecular landscape. 前列腺癌的种族差异：基因和分子状况展望。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-06-20 DOI: 10.1007/s10555-024-10193-8

Jyoti B Kaushal, Pratima Raut, Sakthivel Muniyan, Jawed A Siddiqui, Zahraa W Alsafwani, Parthasarathy Seshacharyulu, Sujit S Nair, Ashutosh K Tewari, Surinder K Batra

{"title":"Racial disparity in prostate cancer: an outlook in genetic and molecular landscape.","authors":"Jyoti B Kaushal, Pratima Raut, Sakthivel Muniyan, Jawed A Siddiqui, Zahraa W Alsafwani, Parthasarathy Seshacharyulu, Sujit S Nair, Ashutosh K Tewari, Surinder K Batra","doi":"10.1007/s10555-024-10193-8","DOIUrl":"10.1007/s10555-024-10193-8","url":null,"abstract":"Prostate cancer (PCa) incidence, morbidity, and mortality rates are significantly impacted by racial disparities. Despite innovative therapeutic approaches and advancements in prevention, men of African American (AA) ancestry are at a higher risk of developing PCa and have a more aggressive and metastatic form of the disease at the time of initial PCa diagnosis than other races. Research on PCa has underlined the biological and molecular basis of racial disparity and emphasized the genetic aspect as the fundamental component of racial inequality. Furthermore, the lower enrollment rate, limited access to national-level cancer facilities, and deferred treatment of AA men and other minorities are hurdles in improving the outcomes of PCa patients. This review provides the most up-to-date information on various biological and molecular contributing factors, such as the single nucleotide polymorphisms (SNPs), mutational spectrum, altered chromosomal loci, differential gene expression, transcriptome analysis, epigenetic factors, tumor microenvironment (TME), and immune modulation of PCa racial disparities. This review also highlights future research avenues to explore the underlying biological factors contributing to PCa disparities, particularly in men of African ancestry.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1233-1255"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. 抗癌药物分类：美国 FDA 和 EMA 批准药物的更新。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-05 DOI: 10.1007/s10555-024-10188-5

Lorena Ostios-Garcia, Daniel Martínez Pérez, Beatriz Castelo, Noelia Hernández Herradón, Pilar Zamora, Jaime Feliu, Enrique Espinosa

引用次数: 0

Failure to progress: breast and prostate cancer cell lines in developing targeted therapies. 进展失败：开发靶向疗法的乳腺癌和前列腺癌细胞系。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-26 DOI: 10.1007/s10555-024-10202-w

Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal

{"title":"Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.","authors":"Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal","doi":"10.1007/s10555-024-10202-w","DOIUrl":"10.1007/s10555-024-10202-w","url":null,"abstract":"Developing anticancer drugs from preclinical to clinical takes approximately a decade in a cutting-edge biomedical lab and still 97% of most fail at clinical trials. Cell line usage is critical in expediting the advancement of anticancer therapies. Yet developing appropriate cell lines has been challenging and overcoming these obstacles whilst implementing a systematic approach of utilizing 3D models that recapitulate the tumour microenvironment is prudent. Using a robust and continuous supply of cell lines representing all ethnic groups from all locales is necessary to capture the evolving tumour landscape in culture. Next, the conversion of these models to systems on a chip that can by way of high throughput cytotoxic assays identify drug leads for clinical trials should fast-track drug development while markedly improving success rates. In this review, we describe the challenges that have hindered the progression of cell line models over seven decades and methods to overcome this. We outline the gaps in breast and prostate cancer cell line pathology and racial representation alongside their involvement in relevant drug development.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1529-1548"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers. 前列腺癌细胞外囊泡的生物功能及其作为诊断和预后生物标志物的临床应用。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s10555-024-10210-w

Patrizia Limonta, Sara Marchesi, Gaia Giannitti, Lavinia Casati, Fabrizio Fontana

{"title":"The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers.","authors":"Patrizia Limonta, Sara Marchesi, Gaia Giannitti, Lavinia Casati, Fabrizio Fontana","doi":"10.1007/s10555-024-10210-w","DOIUrl":"10.1007/s10555-024-10210-w","url":null,"abstract":"Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and main causes of cancer-related deaths worldwide. It is characterized by high heterogeneity, ranging from slow-growing tumor to metastatic disease. Since both therapy selection and outcome strongly rely on appropriate patient stratification, it is crucial to differentiate benign from more aggressive conditions using new and improved diagnostic and prognostic biomarkers. Extracellular vesicles (EVs) are membrane-coated particles carrying a specific biological cargo composed of nucleic acids, proteins, and metabolites. Here, we provide an overview of the role of EVs in PCa, focusing on both their biological function and clinical value. Specifically, we summarize the oncogenic role of EVs in mediating the interactions with PCa microenvironment as well as the horizontal transfer of metastatic traits and drug resistance between PCa cells. Furthermore, we discuss the potential usage of EVs as innovative tools for PCa diagnosis and prognosis.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1611-1627"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis. 微生物组与结直肠癌发生的分子途径之间的功能联系。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI: 10.1007/s10555-024-10215-5

Jessica Permain, Barry Hock, Timothy Eglinton, Rachel Purcell

引用次数: 0

Functional and clinical roles of stromal PDGF receptors in tumor biology. 基质 PDGF 受体在肿瘤生物学中的功能和临床作用。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1007/s10555-024-10194-7

Carina Strell, Elisabet Rodríguez-Tomàs, Arne Östman

{"title":"Functional and clinical roles of stromal PDGF receptors in tumor biology.","authors":"Carina Strell, Elisabet Rodríguez-Tomàs, Arne Östman","doi":"10.1007/s10555-024-10194-7","DOIUrl":"10.1007/s10555-024-10194-7","url":null,"abstract":"PDGF receptors play pivotal roles in both developmental and physiological processes through the regulation of mesenchymal cells involved in paracrine instructive interactions with epithelial or endothelial cells. Tumor biology studies, alongside analyses of patient tissue samples, provide strong indications that the PDGF signaling pathways are also critical in various types of human cancer. This review summarizes experimental findings and correlative studies, which have explored the biological mechanisms and clinical relevance of PDGFRs in mesenchymal cells of the tumor microenvironment. Collectively, these studies support the overall concept that the PDGF system is a critical regulator of tumor growth, metastasis, and drug efficacy, suggesting yet unexploited targeting opportunities. The inter-patient variability in stromal PDGFR expression, as being linked to prognosis and treatment responses, not only indicates the need for stratified approaches in upcoming therapeutic investigations but also implies the potential for the development of PDGFRs as biomarkers of clinical utility, interestingly also in settings outside PDGFR-directed treatments.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1593-1609"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy. 线粒体在肿瘤转移中的作用以及线粒体靶向癌症疗法的进展。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1007/s10555-024-10211-9

Fanglu Chen, Yucheng Xue, Wenkan Zhang, Hao Zhou, Zhiyi Zhou, Tao Chen, Eloy YinWang, Hengyuan Li, Zhaoming Ye, Junjie Gao, Shengdong Wang

引用次数: 0

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets. 转移中的线粒体核糖体蛋白及其作为预后和治疗靶点的潜力。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-10-01 DOI: 10.1007/s10555-024-10216-4

Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin

{"title":"Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets.","authors":"Jasmine M Bacon, Johanna L Jones, Guei-Sheung Liu, Joanne L Dickinson, Kelsie Raspin","doi":"10.1007/s10555-024-10216-4","DOIUrl":"10.1007/s10555-024-10216-4","url":null,"abstract":"The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1119-1135"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lost at SCLC: a review of potential platinum sensitizers. 迷失在 SCLC：潜在铂敏化剂综述。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-08-23 DOI: 10.1007/s10555-024-10207-5

Bryan Oronsky, Nacer Abrouk, Li Mao, Yunle Shen, Xiaohui Wang, Luyang Zhao, Scott Caroen, Tony Reid

引用次数: 0